清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Feasibility of continuing docetaxel-based therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) that experience hypersensitivity reactions (HSR).

作者
Anna Couvillon,Melony A. Beatson,Nancy Harold,Fatima H. Karzai,Ravi Amrit Madan,James L. Gulley,William L. Dahut
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:31 (6_suppl): 132-132
标识
DOI:10.1200/jco.2013.31.6_suppl.132
摘要

132 Background: Patients that receive docetaxel are observed closely for HSRs. Severe HSRs have been reported in patients premedicated with corticosteroids. The rate of allergic reactions reported in the TAX 327 trial (n=332) was 8% (any grade) and 1% (grade 3/4). In TAX 327 treatment was stopped after a total of 10 cycles of docetaxel. A recent trial conducted at the NCI has included patients treated with docetaxel-based therapy until radiographic progression with no cap on total dose or cycle number. Most patients have had significantly more than 10 cycles (median greater than 16 with a range of 1 to 48; however, some cycles did not include docetaxel). Given the increased incidence of HSR to docetaxel on our protocols, we developed guidelines for the clinical management of HSRs to docetaxel. Methods: We reviewed the literature on taxane HSRs and developed a 4-step clinical management guideline for the prevention and treatment of HSRs to docetaxel. Our guidelines utilize increasing amounts of H1/H2 antihistamines, corticosteroids, slower infusion rates of docetaxel, and/or decreasing concentrations of docetaxel. Results: From August 2009 to present, 63 mCRPC patients have been treated with docetaxel-based therapy. Twenty-three patients (37%) have experienced a HSR to docetaxel. HSRs initially occurred at cycle 1 (17%), cycle 2 (48%), cycle 3 (17%), cycle 4 (n=2), cycle 14 (n=1), cycle 16 (n=1). All patients were re-challenged with docetaxel using our 4-step clinical management guideline approach. Ten patients continued docetaxel without further HSRs. The remaining 13 patients continued to experience HSRs but were able to safely complete each infusion of docetaxel. No patients required discontinuation of therapy. Of the 23 patients with HSRs, 21 received more than 10 cycles of therapy with a median of 17 and a range of 1 to 38. Conclusions: Patients with mCRPC disease that is taxane sensitive and who experience HSR to docetaxel can continue to receive docetaxel safely. Most of these patients demonstrated a continued PSA, clinical, and radiographic response to therapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Lucas的应助被王泰一采纳,获得10
3秒前
4秒前
sissiarno完成签到,获得积分0
8秒前
文静文静666完成签到,获得积分10
8秒前
Ruby于完成签到 ,获得积分10
8秒前
RYYYYYYY233完成签到 ,获得积分0
12秒前
15秒前
15秒前
火星上安柏完成签到,获得积分10
17秒前
SHASHA发布了新的文献求助10
19秒前
keyan123完成签到,获得积分10
20秒前
今后的应助被蜗牛好好飞采纳,获得10
21秒前
28秒前
Skywings完成签到,获得积分10
33秒前
33秒前
追梦人2016完成签到 ,获得积分10
35秒前
虚幻烤鸡完成签到,获得积分10
39秒前
超级烨磊完成签到,获得积分10
45秒前
丘比特的应助被下论文好难采纳,获得10
45秒前
简单的冥王星完成签到,获得积分10
1分钟前
1分钟前
1分钟前
王泰一发布了新的文献求助10
1分钟前
1分钟前
maomao发布了新的文献求助20
1分钟前
ZXD1989完成签到 ,获得积分10
1分钟前
甜美忆寒完成签到,获得积分10
1分钟前
RZH完成签到,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
欢呼的晓博完成签到,获得积分10
1分钟前
下论文好难完成签到,获得积分10
1分钟前
zhangguo完成签到 ,获得积分10
2分钟前
无极微光的应助被科研通管家采纳,获得20
2分钟前
噼里啪啦完成签到,获得积分10
2分钟前
痴情的不惜完成签到,获得积分10
2分钟前
2分钟前
明理冰海完成签到,获得积分10
2分钟前
luyun发布了新的文献求助10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173225
求助须知:如何正确求助?哪些是违规求助? 9565567
关于积分的说明 21780511
捐赠科研通 7767377
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555750
邀请新用户注册赠送积分活动 2476697